| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
80.34(B) |
| Last
Volume: |
14,507,907 |
Avg
Vol: |
8,705,604 |
| 52
Week Range: |
$63.5 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,000 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$145,920 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
5 |
9 |
14 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bischofberger Norbert W |
EVP, R&D and CSO |
• • – |
2018-02-21 |
4 |
D |
$80.69 |
$570,559 |
D/D |
(7,071) |
28,995 |
|
- |
|
| Bischofberger Norbert W |
EVP, R&D and CSO |
• • – |
2018-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
23,273 |
36,066 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2018-02-21 |
4 |
D |
$80.69 |
$1,561,674 |
D/D |
(19,354) |
3,017,762 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2018-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
40,010 |
3,037,116 |
|
- |
|
| Alton Gregg H |
EVP,Corporate &Medical Affairs |
• • – |
2018-02-20 |
4 |
S |
$81.54 |
$1,176,992 |
I/I |
(14,435) |
0 |
|
- |
|
| Washington Robin L |
EVP, CFO |
• • – |
2018-02-15 |
4 |
A |
$62.35 |
$21,198 |
D/D |
340 |
9,942 |
|
- |
|
| Alton Gregg H |
EVP,Corporate &Medical Affairs |
• • – |
2018-02-15 |
4 |
A |
$62.35 |
$21,198 |
D/D |
340 |
38,078 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2018-02-15 |
4 |
A |
$62.35 |
$21,198 |
D/D |
340 |
1,166,264 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2018-02-15 |
4 |
A |
$62.35 |
$13,779 |
D/D |
221 |
2,936 |
|
- |
|
| Young Kevin |
Chief Operating Officer |
• • – |
2018-02-15 |
4 |
A |
$62.35 |
$21,198 |
D/D |
340 |
16,152 |
|
- |
|
| Bischofberger Norbert W |
EVP, R&D and CSO |
• • – |
2018-02-15 |
4 |
A |
$62.35 |
$21,198 |
D/D |
340 |
12,793 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2018-02-15 |
4 |
A |
$62.35 |
$21,198 |
D/D |
340 |
2,997,106 |
|
- |
|
| Young Kevin |
Chief Operating Officer |
• • – |
2018-02-10 |
4 |
D |
$79.32 |
$33,711 |
D/D |
(425) |
15,812 |
|
- |
|
| Young Kevin |
Chief Operating Officer |
• • – |
2018-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
908 |
16,237 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2018-02-09 |
4 |
S |
$77.92 |
$4,675,080 |
D/D |
(60,000) |
122,258 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2018-02-09 |
4 |
OE |
$26.62 |
$1,596,900 |
D/D |
60,000 |
182,258 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2018-02-01 |
4 |
AS |
$83.35 |
$4,177,824 |
D/D |
(50,000) |
2,996,766 |
|
- |
|
| Martin John C |
Executive Chairman |
• • – |
2018-02-01 |
4 |
OE |
$23.60 |
$1,180,000 |
D/D |
50,000 |
3,046,766 |
|
- |
|
| Alton Gregg H |
EVP,Corporate &Medical Affairs |
• • – |
2018-02-01 |
4 |
AS |
$83.29 |
$2,087,860 |
D/D |
(25,000) |
37,738 |
|
- |
|
| Alton Gregg H |
EVP,Corporate &Medical Affairs |
• • – |
2018-02-01 |
4 |
OE |
$40.56 |
$699,660 |
D/D |
17,250 |
62,738 |
|
- |
|
| Young Kevin |
Chief Operating Officer |
• • – |
2018-02-01 |
4 |
D |
$83.49 |
$18,201 |
D/D |
(218) |
15,329 |
|
- |
|
| Young Kevin |
Chief Operating Officer |
• • – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
620 |
15,547 |
|
- |
|
| Young Kevin |
Chief Operating Officer |
• • – |
2018-01-31 |
4 |
D |
$83.80 |
$189,304 |
D/D |
(2,259) |
14,927 |
|
- |
|
| Young Kevin |
Chief Operating Officer |
• • – |
2018-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
7,110 |
17,186 |
|
- |
|
| Meyers James R |
EVP Worldwide Commercial Ops |
• • – |
2018-01-16 |
4 |
AS |
$80.00 |
$8,024,364 |
D/D |
(100,000) |
2,715 |
|
- |
|
1105 Records found
|
|
Page 21 of 45 |
|
|
0.19 (0.3%) 
